medigraphic.com
ISSN 2954-3835 (Electronic)
ISSN 2683-2828 (Print)

2020, Number 2

<< Back Next >>

Cardiovasc Metab Sci 2020; 31 (2)

Prevalence and clinical-therapeutic profile of atrial fibrillation in private cardiology offices in northeast Mexico

Solís OCA, Ramírez RSA, Carrillo PMA, Solís SJM

Language: English
References: 23
Page: 40-48
PDF size: 440.39 Kb.


ABSTRACT

Introduction: The prevalence of atrial fibrillation (AF) in Mexico is unknown. Objectives: To document AF prevalence and a clinical-therapeutic profile. Methods: Cross-sectional study in three private cardiology offices in Northeast Mexico; in 337 patients from 8,999 clinical records, AF was documented. Results: AF prevalence was 3.74%, permanent 56.0%, paroxistic 28.4%, persistent 15.7%; non valvular atrial fibrillation (NVAF) 94.06%. Age 74 ± 12.89 years, women 52.22%, hypertension, 74.18%, smoking, 36.79%, alcoholism 35.01% and type 2 diabetes, 30.56%. The CHA2DS2-VASc ≥ 2 group vs 0-1, received more anticoagulant (OAC) (31.88 vs 8.33%) and new oral anticoagulant (NOAC) (53.31 vs 13.33%) p ‹ 0.01 for both. In ages 60-75, the CHA2DS2-VASc ≥ 2 group vs 0-1, received more OAC (34.89 vs 6.25%) p = 0.0004, and NOAC (54.16 vs 0%) p ‹ 0.01. The CHADS group ≥ 2 vs 0-1, used more OAC (33.6 vs 18.8%) and NOAC (55.17 vs 34.11%) p ‹ 0.01 for both and vitamin K antagonist (VKA) (12.06 vs 3.5%) p = 0.004. The CHA2DS2-VASc group ≥ 2 vs 0-1, had more women than men (95.03% versus 85.9%), received more diuretics (57.49 vs 13.33), mineralocorticoid receptor antagonist (MRA) (27.52 vs 0%) and angiotensin receptor blockers (ARB) (55.40 vs 16.66%) p ‹ 0.01 for all. Conclusion: In our patients, AF is characterized by having a clinical profile of high cardiovascular risk, alcoholism, senility and predominance of women, with a prevalence (3.74%) similar to that of other western countries.


REFERENCES

  1. Du X, Dong J, Ma C. Is atrial fibrillation a preventable disease? J Am Coll Cardiol. 2017; 69: 1968-1982.

  2. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014; 6: 213-220.

  3. Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015; 4 (1): e001486.

  4. Lip GY, Bawden L, Hodson R, Rutland E, Snachtfold J, Beevers DG. Atrial fibrillation amongst the Indo-Asian general practice population: the West Birmingham Atrial Fibrillation Project. Int J Cardiol. 1998; 65: 187-192.

  5. González-Hermosillo JA, Márquez MF, Ocampo-Peña S. Design of an atrial fibrillation and embolic risk registry in México: CARMEN-AF. Arch Cardiol Mex. 2017; 87 (1): 5-12.

  6. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC et al. 2019 AHA/ACC/HRS focused update if the 2014 guideline for management of patients with atrial fibrillation: a report of American College of Cardiology Foundation/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2019; 16 (8): e66-e93.

  7. Maura G, Billionnet C, Drouin J, Weill A, Neumann A, Pariente A. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016. BMJ Open. 2019; 9 (4): e026645.

  8. Rodriguez Diez G, Márquez MF, Iturralde P, Molina L, Pozas G, Cordero Cabra A et al. Joint Mexican Position document on the treatment of atrial Fibrillation. Endorsed by: Mexican National Association of Cardiologist (ANCAM), Mexican Electrophysiology and Pacing Society (SOMEEC) and Mexican Society of Cardiology (SMC). Cardiovasc Metab Sci. 2019; 30 (3): 91-99.

  9. Steinberg BA, Gaor H, Shrader P, Pieper K, Thomas L, Camm AJ et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF 1, AND ORBIT-AF II, registres. Am Heart J. 2017; 194: 132-140.

  10. Jackson LR, Peterson ED, Okeagu E, Thomas K. Review of race/ethnicity in non vitamin K antagonist oral anticoagulantes clinical trials. J Thromb Thrombolysis. 2015; 39 (2): 222-227.

  11. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365 (11): 981-992.

  12. Amponsah MK, Benjamin EJ, Magnani JW. Atrial fibrillation and race - A contemporary review. Curr Cardiovasc Risk Rep. 2013; 7 (5). doi: 10.1007/s12170-013-0327-8.

  13. Martínez CAA, Lanas F, Radaideh G, Kharabsheh SM, Lambelet M, Viaud MAL et al. XANTUS-EL: a real-world prospective, observational study of patients treated with rivaroxabán for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. Egypt Heart J. 2018; 70 (4): 307-313.

  14. Lara-Vaca S, Cordero Cabra A, Martínez-Flores E, Iturralde Torres P. Registro Mexicano de Fibrilación Auricular (ReMeFa). Gac Med Mex. 2014; Suppl 1: 48-59.

  15. Sardar MR, Badri M, Prince CT, Seltzer J, Kowey PR. Underrepresentation of women, elderly patients and racial minorities in the randomized trial used for cardiovascular guidelines. JAMA Int Med. 2014; 174 (11): 1868-1870.

  16. Simmons A, Falbe J, Vacek J. Coronary artery disease in women: a review and update. Rev Cardiovasc Med. 2011; 12 (2): e84-e93.

  17. Li YM, Jiang C, He L, Li XX, Hou XX, Chang SS et al. Sex differences in presentation, quality of life, and treatment in Chinese atrial fibrillation patients: insights from the China Atrial Fibrillation Registry study. Med Sci Monit. 2019; 25: 8011-8018.

  18. García M, Mulvagh SL, Merz NB, Buring JE, Manson JE. Cardiovascular disease in women: clinical perspectives. Circ Res. 2016; 118 (8): 1273-1293.

  19. Ko D, Rahman F, Martins MA, Hylek EM, Ellinor PT, Schnabel RB et al. Atrial fibrillation in women: treatment. Nat Rev Cardiol. 2017; 14 (2): 113-124.

  20. Cheng EY, Kong MH. Gender differences of thromboembolic events in atrial fibrillation. Am J Cardiol. 2016; 117 (6): 1021-1027.

  21. Volterrani M, Iellamo F, Rosano G, Guarini P, Pusineri E, Bonassi S et al. Anticoagulation in “real world” patients with atrial fibrillation in Italy: results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. Int J Cardiol. 2013; 168 (5): 4729-4733.

  22. Cools F, Wollaert B, Vervoort G, Verstraete S, Voet J, Hermans K et al. Treatment patterns in anticoagulant therapy in patients with newly diagnoses atrial fibrillation in Belgium: results from the GARFIELD-AF registry. Act Cardiol. 2019; 74 (4): 309-318.

  23. Bassand JP, Acceta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA et al. Two year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016; 37 (38): 2882-2889.




2020     |     www.medigraphic.com